Back to top

Analyst Blog

In the second quarter of 2013, BioScrip Inc. (BIOS - Analyst Report) posted adjusted loss per share of 2 cents, flat year over year. However, the result was worse than the Zacks Consensus Estimate of earnings of 3 cents per share.

On a reported basis, BioScrip’s net loss from continuing operations of $8.3 million or 13 cents per share was wider than the net loss of $4.3 million or 7 cents per share in the year-ago quarter.

Total revenue rose 22.3% year over year to $190.7 million in the second quarter, trailing well behind the Zacks Consensus Estimate of $206 million. In the second quarter, solid revenue growth was attributable to higher contributions from Infusion Services and Home Health Services business.

The company recorded a robust hike of 40.7% in Infusion Services revenues to $156.2 million on the back of organic volume growth and accretive acquisitions. Revenues from the Home Health Services segment rose 8.1% to $18.2 million, led by volume growth from private duty nursing activity. Lastly, revenues from the PBM Services segment were $16.3 million, down 42% from the prior-year quarter. The decline was due to lower sales volume of discount cards, loss of a client and decrease in funded PBM business.

While the cost of product revenues shot up 36.7% to $102.7 million, the cost of service revenues declined 17.1% to $23 million in the quarter. Gross profit during the quarter rose 22.6% to $65 million with 10 basis points (bps) expansion in gross margin to 34.1%.

Selling, general and administrative (SG&A) expenses increased 27% to $56 million. The surging SG&A resulted in a 50 bps drag in adjusted operating margin in the quarter to 2.8%.

Exiting the quarter, BioScrip had cash balance of $81.6 million compared with $62.1 million at the end of 2012. The company’s long-term debt was $225.5 million compared with $226.4 million at the end of 2012.


For 2013, BioScrip continues to expect revenues of $830–$865 million, reflecting growth in the range of 25%-30%. The current Zacks Consensus Estimate is pegged at $838 million.

Our Take

BioScrip reported a disappointing quarter missing the Zacks Consensus Estimate on both fronts by a sizeable margin. Further, losses worsened in the quarter. PBM business also continued to decline.

On the bright side, another quarter of strong top-line growth, with most of the upside from the Infusion business, was encouraging. We also look forward to accretion from recent acquisitions.

Currently, the stock carries a Zacks Rank #3 (Hold). While we remain on the sidelines for BioScrip, other stocks such as McKesson Corporation (MCK - Analyst Report), Herbalife Ltd. (HLF - Snapshot Report) and GNC Holdings Inc. (GNC - Snapshot Report) warrant a look. These stocks carry a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SIGNET JEWE… SIG 116.37 +7.72%
CHYRONHEGO… CHYR 2.72 +5.84%
US SILICA H… SLCA 70.72 +4.00%
MALLINCKROD… MNK 80.11 +2.32%
RF MICRO DE… RFMD 11.76 +2.31%